AGILON HEALTH Reports USD 1149.0 Million in Total Revenue and -16.8 Million Net Income for Q2 FY2023
August 6, 2023
🌥️Earnings Overview
For the second quarter of FY2023, ending June 30th 2023, AGILON HEALTH ($NYSE:AGL) reported total revenue of USD 1149.0 million and a net income of USD -16.8 million. This was a 71.5% increase in revenue compared to the same period last year and a decrease of -20.6 million in net income.
Stock Price
On Thursday, AGILON HEALTH reported their financial results for the second quarter of fiscal year 2023. The company reported total revenue of USD 1149.0 million, a decrease of 16.8% compared to the same period last year. In response to these results, the stock price of AGILON HEALTH opened at $19.3 and closed at $19.1, down by 1.4% from the prior closing price of 19.3. This suggests that investors are disappointed in the financial performance of the company, which may be attributed to the decrease in revenue and net income. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Agilon Health. More…
| Total Revenues | Net Income | Net Margin |
| 3.67k | -87.86 | -2.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Agilon Health. More…
| Operations | Investing | Financing |
| -129.33 | -169.69 | -183.46 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Agilon Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.35k | 1.47k | 2.17 |
Key Ratios Snapshot
Some of the financial key ratios for Agilon Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 50.5% | – | -2.2% |
| FCF Margin | ROE | ROA |
| -4.1% | -5.2% | -2.2% |
Analysis
At GoodWhale, we conducted an analysis of AGILON HEALTH‘s financials and based on our Star Chart assessment, AGILON HEALTH has an intermediate health score of 6/10, meaning it might be able to sustain future operations in times of crisis. AGILON HEALTH is strong in asset and growth, but weak in dividend and profitability. After further review, we have classified AGILON HEALTH as a ‘cheetah’, a type of company that achieved high revenue or earnings growth but considered to be less stable due to lower profitability. Given the overall health score of 6/10 and its classification as a ‘cheetah’, we suggest that investors who are looking for high-risk, high-reward investments should consider AGILON HEALTH. These investors may potentially receive higher returns for taking on the risk, but should also be prepared to accept potentially higher losses if things don’t turn out as planned. More…
Peers
Its competitors include P3 Health Partners Inc, Oak Street Health Inc, and Pathway Health Corp.
– P3 Health Partners Inc ($NASDAQ:PIII)
P3 Health Partners Inc is a US-based healthcare company that provides services and products to health plans, provider groups, and individuals. The company has a market capitalization of 212.47 million as of 2022 and a return on equity of 196.33%. P3 Health Partners Inc is a leading provider of healthcare services and products in the United States. The company offers a wide range of services and products, including health insurance, provider services, and individual products. P3 Health Partners Inc is a publicly traded company listed on the New York Stock Exchange.
– Oak Street Health Inc ($NYSE:OSH)
Oak Street Health Inc is a healthcare services company that operates primary care centers for adults on Medicare in the United States. As of December 31, 2020, the company operated 109 primary care centers in Illinois, Indiana, Michigan, New Jersey, Pennsylvania, and Rhode Island. The company was founded in 2013 and is headquartered in Chicago, Illinois.
– Pathway Health Corp ($TSXV:PHC)
Pathway Health Corp has a market cap of 4.69M as of 2022, a Return on Equity of -239.69%. The company provides healthcare services to skilled nursing and assisted living facilities.
Summary
Investors looking to invest in Agilon Health should take notice of its recent Q2 financial results. Total revenue for the quarter ending June 30, 2023 was up 71.5% over the same period last year, coming in at USD 1149.0 million. Net income was down from the same period, at -16.8 million, a decrease of -20.6 million compared to the same period last year.
Although net income is down, the substantial increase in revenue suggests that Agilon Health is continuing to grow and expand its customer base. Investors should consider this data when making their decisions.
Related Posts
Recent Posts
